Cell therapy weekly: US FDA halts Phase I trial of CAR-T therapy for multiple myeloma over patient death

This week: the US FDA halts an investigational CAR-T therapy for multiple myeloma due to a patient death, a stem cell clinic has been sued over making false and misleading claims regarding their stem cell products, hematopoietic stem cells (HSCs) have been found to be more robust at expanding than those in cord blood, and a landmark patent has been filed for stem cell-based immunotherapy of schizophrenia. The news highlights: US FDA halts Phase I trial of CAR-T therapy for multiple myeloma over patient death Elite Integrated Medical sued over deceptive claims surrounding their stem cell products HSCs obtained from...